A first-of-its-kind trial has demonstrated that a receptor involved in the brain’s reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders. This innovative fast-fail trial was funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, and the results of the trial are published in Nature Medicine.
There has been a lot of recent interest in the use of psychedelic drugs to treat depression. A new study suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.READ MORE
Using a newly developed laboratory model of three types of brain cells, Penn and CHOP scientists reveal how HIV infection—as well as the drugs that treat it—can take a toll on the central nervous system.
Women who suffer from psychiatric disorders such as depression, anxiety, mania and schizophrenia following the live birth of their first child are less likely to go on to have more children, according to the first study to investigate this in a large nationwide population.READ MORE
Researchers at Karolinska Institutet and St Erik Eye Hospital in Sweden have discovered a way to refine the production of retinal cells from embryonic stem cells for treating blindness in the elderly.READ MORE
Technique may enable speedy, on-demand design of softer, safer neural devices.
A recent study finds that people who balance living in the moment with planning for the future are best able to weather daily stress without succumbing to negative moods.
An international collaborative study provides findings on the neural basis of intelligence, otherwise known as general cognitive ability (IQ).
Ozanimod is the latest in a series of novel medicines to originate from the laboratories of Scripps Research.